好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Safety of Using Disease-Modifying Therapy Post-Alemtuzumab Treatment in Patients with Active Relapsing-Remitting Multiple Sclerosis in the Alemtuzumab Clinical Development Program
Multiple Sclerosis
(-)
185
Authors/Disclosures
Ann D. Bass, MD (Lone Star Neurology - San Antonio)
PRESENTER
Dr. Bass has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion, Amgen, Bristol-Myers-Squibb, EMD Serono, Novartis, Roche-Genentech, Sanofi-Genzyme, TG Therapeutics. Dr. Bass has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen, Alexion, EMD Serono, Novartis, Roche-Genentech, Sanofi-Genzyme, TG Therapeutics. Dr. Bass has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Alexion, Amgen, Bristol-Myers-Squibb, EMD Serono, Roche-Genentech, Sanofi-Genzyme, TG Therapeutics. The institution of Dr. Bass has received research support from Bristol-Myers-Squibb, EMD Serono, Novartis, Roche-Genentech, Sanofi-Genzyme, TG Therapeutics.
Keith R. Edwards, MD, FAAN (MS Center of Northeastern New York) No disclosure on file
Bhupendra O. Khatri, MD, FAAN (Center for Neurologic Disorders/St. Francis OP Center) Dr. Khatri has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Alexion. Dr. Khatri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Khatri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Khatri has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for ER Squibb (Bristol Myer Squibb). Dr. Khatri has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizone. Dr. Khatri has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Khatri has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. Dr. Khatri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genzyne. Dr. Khatri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Khatri has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genzyme. Dr. Khatri has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Alexion. Dr. Khatri has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Khatri has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Seronoe. Dr. Khatri has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for E.R. Squibb. Dr. Khatri has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Horizon. Dr. Khatri has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Janssen. Dr. Khatri has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TG Therapeutic. Dr. Khatri has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genzyme. Dr. Khatri has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Khatri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Argenx US. The institution of Dr. Khatri has received research support from Biogen.
Krzysztof W. Selmaj (University of Warmia and Mazury) Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
David H. Margolin, MD, PhD (Genzyme Corporation) Dr. Margolin has received personal compensation for serving as an employee of uniQure, Inc.. Dr. Margolin has stock in Cerevance, Inc. Dr. Margolin has stock in Datacubed Health. Dr. Margolin has stock in uniQure, Inc.. Dr. Margolin has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
Per Soelberg Sorensen No disclosure on file